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Both positive and negative results have been reported in the literature from the use of acupressure at the P6 point, providing evidence of highly suggestive but not conclusive results. 
Objectives: to clarify whether acupressure is effective and cost-effective in the management of chemotherapy-related nausea and vomiting.
Methods:
A randomised three-group sham-controlled trial was designed to test the effects of acupressure in the management of chemotherapy-related nausea and vomiting. Patients with cancer receiving low, moderate and highly emetogenic chemotherapy were randomised to receive, in addition to standardised antiemetics, either acupressure wristbands, sham acupressure wristbands or antiemetics alone. Primary outcome assessment was carried out daily for 7 days per chemotherapy cycle over four cycles using the Rhodes Index for Nausea & Vomiting. Other assessments, completed at day 6 of each of the four cycles, included the MASCC Antiemesis Tool, and the FACT-G quality of life scale.
Results:
500 patients were randomised in the three study groups. Primary outcome analysis (nausea in cycle 1) revealed no statistically significant differences between the three groups, although nausea levels in the proportion of patients using wristbands (both real and sham ones) was somewhat lower than in the antiemetics only group. Adjusting for gender, age and emetic risk of the chemotherapy, the odds ratio (O.R.) of lower nausea experience was 1.18 for the acupressure group and 1.42 for the sham acupressure group. A gender interaction effect was evident in the data (P=0.002). No significant differences were detected in relation to vomiting outcomes, anxiety, and quality of life measures. 
Conclusions
No clear recommendations can be made about the use of acupressure wristbands in the management of chemotherapy-related nausea and vomiting, as results did not reach statistical significance. However, the study provided evidence of encouraging signals in relation to improved nausea experience and warrantees further consideration both in practice and in further clinical trials.

The effectiveness and cost effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: a randomised controlled trial

Introduction
Significant developments in antiemetic therapy over the past two decades have improved the control of chemotherapy-related vomiting. By contrast, chemotherapy-related nausea, both acute and delayed, is still a significant problem in clinical practice, with 42–52% of patients experiencing nausea on any one day in routine practice1. Surprisingly, despite improvements in the management of vomiting, post-chemotherapy nausea seems to have increased2. Furthermore, clinicians often underestimate the experience of nausea, especially with regards to delayed nausea3,4.

Chemotherapy-induced nausea and vomiting (CINV) can have a profound effect on the cancer treatment experience5 and is associated with negative effects on daily life and overall quality of life, including effects on food intake, weight loss, effects on social interactions, dehydration, difficulty with sleeping and anxiety5,6. In a qualitative study of patients’ experiences, unmanaged nausea was constant in some patients and made them exhausted for long periods after chemotherapy, making recovery between cycles longer5. The impact of nausea is greater than that of vomiting7 and nausea has proven to be more difficult to control. The direct and indirect costs of the experience of nausea and vomiting, especially of delayed symptoms, are considerable8. Antiemetic trials have traditionally focused primarily on vomiting and emetic episodes, upon which the effectiveness of many antiemetic drugs is judged. Little attention has been directed to the concept of chemotherapy-induced nausea despite the fact that it is increasingly recognised that nausea and vomiting are related but separate entities9,10.  The need for these two symptoms to be treated as two separate entities is strongly advocated10.  





1.	To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
Secondary objectives:
2.	To assess the level of quality of life and psychological distress in patients using acupressure wristbands in addition to standard care in the management of chemotherapy-induced nausea and vomiting compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
3.	To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) vomiting compared to patients receiving standard care with sham acupressure wristbands and standard care alone.
4.	To ascertain for which emetogenic level of chemotherapy regimens (ie. high, moderate or low emetogenic chemotherapy), gender or age group self-acupressure using wristbands in addition to standard care is more or less effective in terms of nausea compared to patients receiving standard care with sham acupressure wristbands and standard care alone.

Research methods
Design of the study
The design of the study was a randomised controlled trial with 3 arms. Each arm consisted of usual care plus one of (1) acupressure wristbands, (2) sham acupressure wristbands, and (3) no additional treatment. The duration of the patients’ involvement was for four cycles of chemotherapy. Subjects were allocated to the trial groups through computer-generated randomisation carried out remotely by the trials unit of the Christie Hospital NHS Foundation Trust. Randomisation was independent and the randomisation method used consisted of minimisation with a random element (stochastic minimisation), balancing for gender25,26, age (16-24; >24-50; >50)25,27 and three levels of emetogenic chemotherapy (low, moderate and high according to international ASCO and MASCC classifications)28,29.

Sample: 
The target population was a heterogeneous group of cancer patients meeting inclusion criteria and about to receive chemotherapy of high, moderate and low emetogenic potential. Heterogeneity is important in order to address issues of response to different types of emetogenic chemotherapy, and by gender and age, as past literature highlights these are important in assessing the effectiveness of treatments for chemotherapy-related nausea and vomiting.

In the acupressure group, in addition to standard antiemetics, patients were provided with a pair of widely available acupressure wristbands. These bands are elastic wristbands with a 1cm protruding round plastic button (stud). These are available in two sizes, a standard one and a larger one. Patients wore the wristband with the stud pressing the P6 acu-point, which is located on the anterior surface of the forearm, approximately three-finger width up from the crease of the wrist between the tendons of the Palmaris longus and flexor carpi radialis. Patients were provided with a pair of acupressure wristbands and they were instructed to wear them on both arms and take them off only when showering/bathing. An instruction sheet with a picture of point P6 and how to locate the point was also provided to patients. Patients were instructed to wear the wristbands from the morning before chemotherapy administration and for the subsequent 6 days (total=7 days). No other complementary therapies use was recommended during the course of acupressure (although any such use was documented). 

In the sham acupressure group, in addition to standard antiemetics, patients were provided with a pair of the identical appearing wristbands, with the only difference being that the sham wristband had the button in the exterior of the wristband and patients were instructed to wear the wristband with the button away from what is the P6 point. An assessment of blinding at the end of the trial was not conducted as patients had not been informed of the use of both sham and real acupressure bands during the trial, but had instead been informed that two different types of wristbands were being evaluated in the trial, with the approval of the Ethics Committee. Clinicians did not know the patients’ group allocation.

The control group received standard antiemetics alone. Standard antiemetics for all three groups were based on ASCO and MASCC international antiemetic guidelines28,29 with the exception of NK1 receptor antagonists (ie. aprepitant) recommended in highly emetic chemotherapy, which was not widely used in the UK hospitals. All patients received rescue antiemetics if nausea and/or vomiting was persistent and failed to respond to the antiemetic treatment (ie. severe nausea or >5 vomiting episodes), based on the experience of each clinician.

Inclusion criteria:
Patients scheduled to receive their first chemotherapy cycle
Patients scheduled to receive highly, moderately and low emetogenic chemotherapy (as per ASCO and MASCC classifications)
Patients scheduled to receive a chemotherapy regime given as a single or multiple administration repeated in 2, 3 or 4-week cycles
Patients who were acupressure wristband-naïve (in terms of never having tried for themselves such a wristband, although they may have seen or heard about such wristbands)
Patients of either gender and older than 16 years old
Patients with any cancer diagnosis receiving chemotherapy without concurrent use of radiotherapy 
Patients receiving chemotherapy as outpatients or inpatients
Patients who were willing to participate in the study and be randomised into one of the three study groups

Exclusion criteria:
Patients scheduled to receive radiotherapy concurrently with chemotherapy and during the assessment period of four cycles for each patient
Patients unable to self care (ie. unable to use wristbands appropriately; mental incapacity preventing continuous and optimal use of wristbands) as judged by the investigators
Patients with liver disease (as nausea is common presenting symptom)
Patients with metabolic risk factors for nausea (ie. electrolyte imbalances causing nausea/vomiting)
Patients with mechanical risk factors for nausea (ie. intestinal obstruction)
Patients experiencing nausea and/or vomiting due to use of opioids
Patients with lymphoedematous arms
Patients with chronic alcohol use (chronic alcohol use is associated with minimal levels of nausea and/or vomiting).

Sample size 
In our pilot study13, the mean score for nausea experience averaged over 5 days was 2.79 (weighted average SD 3.15) in the control group and 1.45 (weighted average SD 2.76) in the intervention group.  At least 135 participants per arm would be required to detect this pair wise difference between arms using a t-test with a conservative Bonferroni-adjusted significance level of 0.05/3 = 0.017 at a power of 90%.  The pilot study suggested an attrition rate of 33%, hence initially at least 202 participants would be required per arm. As the standard deviations (SDs) are much larger than the means in the pilot data, they are suggestive of highly skewed distributions; hence the equivalent nonparametric test (the Mann-Whitney test) would be used. As the asymptotic relative efficiency of the Mann-Whitney test is at worst 0.864, the sample size for a Mann-Whitney test is, in the worst case, equal to the sample size for the t-test divided by 0.864.  This would increase the required sample size to 156 per arm before attrition, 233 after attrition, totaling 699 across the three arms. Due to slower recruitment rate than envisaged initially, it was felt that rethinking of the sample size requirements was necessary. The clinical trials unit analysed the first 141 cases which provided complete data over all four cycles. The Standard Deviation for this cohort of patients was 2.75, slightly lower that the SD of 3 that we included in the initial power calculations. We had also calculated the power of the study to 90%, whereas the standard power in most studies is 80%. We adjusted this number down to 80% power. With these adjustments in mind, the sample required was at 480 participants. 

There were 361 cases with data on the primary outcome (117, 118 and 126 in the three trial arms respectively). Pairwise trial arm comparisons were planned and as the data are skewed a nonparametric test (Mann-Whitney) will be used and this has an asymptotic relative efficiency of at worst 0.864 compared to the t-test. Thus our effective sample sizes are around 117 x 0.864 which is about 100. With such a sample size there is approximately 80% power to detect a standardized difference in means of 0.46 in a two-tail test at the 0.017 level of significance. Recruitment took place in a large cancer hospital in the UK, and 14 cancer units or centres of district general hospitals and university hospitals.

Statistical analysis 
Descriptive statistics have been estimated for all baseline socio-demographic and clinical variables by arm, and for outcome variables (scores on nausea and vomiting subscales) by arm. The association between baseline socio-demographic or clinical variables and outcome variables has been assessed using between-group tests or correlations depending on skewness.  Primary outcome variables have been compared between the arms using t-tests, one-way analysis of variance, Mann-Whitney tests and Kruskal-Wallis tests, bearing in mind any skewness in the data. Ordinal regression models were employed to permit covariate adjusted analyses of a grouped version of the primary outcome. An extension of the proportional odds regression model was used for longitudinal analyses over cycles and this was fitted with a Generalised Estimating Equation (GEE) approach. An intention-to-treat analysis model has been followed. As the primary outcome variable was assessed over several days repeatedly, an aggregate score of all assessments in each cycle was calculated before any modeling analysis.

The effect of missing values was assessed by comparing the numbers and percentages of participants with missing values in the three arms of the study; differences in baseline variables between participants with observed and missing outcomes in each arm; and for participants with observed outcomes, differences in baseline variables between the three arms.  There were no clear associations between known predictors of nausea and cases missing the nausea primary outcome. This fact along with the highly non-normal distribution of the primary response (for which imputation methods are not so well developed) informed our decision to not apply multiple imputation analyses. 

Outcome measures
The Rhodes Index of Nausea, Vomiting and Retching was used as primary outcome measure30. This is an 8-item validated scale measuring nausea and vomiting experience, incidence and severity. In this study, the Nausea experience subscale has been used for power calculations of the sample size, using the mean score across all assessment days in each cycle as the end point. It was completed daily from the day before chemotherapy (to capture any anticipatory nausea) up to seven days post chemotherapy i.e. 8 assessments/cycle.

Secondary outcomes:
MASCC Antiemesis Tool (MAT) 
This is a scale designed by the Multinational Association of Supportive Care in Cancer (MASCC) 31. This 8-item scale assesses in a simple way both acute and delayed nausea and vomiting incidence and extent and was designed specifically for chemotherapy-related nausea and vomiting. The MAT is designed to be used once-per-cycle with retrospective patient recall of events, minimising the patient burden. The scale was completed at day 10 of each cycle (=4 assessments).

FACT-G quality of life scale. 
This is a well-validated quality of life scale focusing on functional assessment32. This scale was completed at baseline and then at day 10 of each cycle (=5 assessments).

Hospital Anxiety & Depression Scale33. 
This is a 14-item scale assessing anxiety with 7 items and depression with a further 7 items. There are separate scores for anxiety and for depression33 and was completed at day 10 of each cycle.

Patient Expectations of Nausea/Vomiting. 
As this is a key risk factor identified in the literature25,34, a 2-item scale was developed assessing the patient expectation for nausea and vomiting, measured on a 10-point ordinal scale . Patients were also asked how much they believed this method had helped them alleviate nausea and how much faith they had in complementary therapies using 10-point scales.
 
Sociodemographic and treatment characteristics were obtained from the patients’ records and the patients themselves. These included gender, age, educational level, marital status, experience with nausea in the past such as during pregnancy, motion sickness or nausea when eating certain foods, use of/experience with other complementary therapies in the past, cancer diagnosis, stage of disease, and chemotherapy protocol used and dosage. Medication use  (standard and rescue antiemetics) during study participation were obtained from the pharmacy records. Furthermore, although not formally required, researchers were asking patients for any side effects (or patients could volunteer side effect information) and these were recorded in a descriptive manner.




500 cases were randomised (166 Standard care [None], 166 Sham acupressure [Sham] and 168 Acupressure [Acu] groups).  A participant flow diagram (Figure 1; CONSORT diagram) shows the numbers of participants recruited and randomly assigned to the three trial arms and who received the intended interventions and were analysed for the primary outcome.


INSERT FIGURE 1 HERE


Descriptive statistics by trial arm

The majority of the participants were females, married and older than 50 years old. The key diagnoses of the sample included breast and colorectal cancer and the majority had received moderately emetogenic chemotherapy (including anthracycline-based chemotherapy). Other sociodemographic can clinical data can be seen in Table 1.

INSERT TABLE 1 HERE

Assessment of missing data for the primary outcome
500 cases were randomised but there was only data for 361 of these for the primary outcome i.e. around 28% of cases are missing the primary outcome. Table 2 illustrates the proportion of cases missing the primary outcome by various factors thought to influence nausea propensity for the remaining 497 cases. There were no marked associations of any of these factors with the probability of missing the primary outcome. 

INSERT TABLE 2 HERE

Nausea experience
Table 3 shows the mean nausea experience of the patients using the Index of Nausea, Vomiting and Retching scale. Scores can be from 0-12, with higher scores indicating higher levels of nausea. Both the sham and acupressure arms had less nausea experience compared to the standard care arm, although this did not reach statistical significance. To note that these mean values represent very low levels of nausea. Only at cycle 4 results become significant (P<0.05) with the acupressure group having no nausea experience reported.

Primary outcome analysis
The primary outcome is the mean Rhodes (Index of Nausea, Vomiting and Retching scale) nausea experience (days 0 to 6) for cycle 1. The possible range for values is 0 to 12 but in fact 111/361 (31%) are exactly zero and around half of all values are less than 1. No transformation would be successful in normalising such a distribution.  The distribution by trial arm is shown in figure 2. Due to the highly skewed distribution the non-parametric Kruskal-Wallis test has been used for the primary comparison of the trial arms. This overall test is non-significant (p=0.14). Provision for pairwise comparisons (Mann-Whitney U tests) with a Bonferroni adjustment was made in the trial design: None v Acupressure (p=0.23), None v Sham acupressure (p=0.05), Sham v Acupressure (p=0.40). It should be noted that the reference value for statistical significance is 0.017 and so none of these pairwise comparisons are statistically significant.
INSERT FIGURE 2 HERE

Regression analyses for the nausea primary outcome data
The approach adopted for this analysis is to group the values into five ordered categories and to utilize regression methods for ordinal data. The first category “Zero” was chosen as it represented no nausea at all and there was a large fraction of cases that fell into such a category (31%). The choice of the other categories was somewhat arbitrary. Five categories are fairly typical for ordinal regression models in the literature and it is desirable that no category has a very small frequency. Category five has a broad range but only 8% cases; subdividing it further would be counter-productive. Having chosen the lowest and highest categories the remaining three were simply selected to have equal width. The main tool used was the proportional odds regression model.35

Unadjusted fit model using all the available data (n=361) showed that the likelihood ratio test for the trial arm effects is non-significant (p=0.34). Furthermore, the estimated odds ratio of a lower (i.e. better) score for Acupressure compared to control are e0.2418 = 1.27 , 95% CI (0.80, 2.03) and the estimated odds ratio of a lower (i.e. better) score for Sham Acupressure compared to control are e0.3354 = 1.40 , 95% CI (0.87, 2.24). Hence, patients in the acupressure arm are 27% more likely to have less nausea/vomiting than the control arm and the sham arm 40%.

Adjusted fit model (for age, gender and emetogenic risk) using all the available data (n=361) showed that, irrespective of arm allocation, subjects that were older than 50 years old (P=0.0005) and male (P=0.005) had better nausea outcome. The emetogenicity of the chemotherapy was also significant factor to the nausea outcome (P=0.013). The estimated odds ratio of a lower (i.e. better) score for Sham Acupressure compared to control (for identical age group, gender and emetogenic risk group) is e0.3520 = 1.42 , 95% CI (0.88, 2.30). Hence, considering the above three risk factors and the adjusted data presented earlier, patients in the acupressure arm are 18% more likely to have less nausea/vomiting than the control arm and the sham arm 42%.

It is of interest to consider the impact of adding a trial arm x term interaction effect to the fitted model for each of age group, gender and emetogenic risk group in turn. A regression analysis indicated that there is evidence to suggest that treatment effects may vary with gender (P=0.002). Adjusted fit model (age, gender, emetogenic risk, cycle frequency, anxiety and nausea expectation) of all the available data (n=315) showed that age >50 years old (P=0.025), male gender (P=0.038), and lower expectation of nausea (P=0.002) are significantly linked with lower levels of nausea. The role of the emetogenicity of the chemotherapy in this analysis was borderline non-significant (P=0.067). Based on this analysis, patients in the acupressure arm are 14% more likely to have less nausea/vomiting than the control arm and the sham arm 30%.

Longitudinal regression analyses of mean Rhodes nausea experience scores
The mean Rhodes nausea experience (days 0 to 6) have also been calculated for cycles 2, 3 and 4. Once again the scores for each cycle have been grouped in the same manner as previously to a five point ordinal scale. These repeated ordinal data have been analysed using an extension of the proportional odds regression model described previously this time fitted using a Generalised Estimating Equation (GEE) approach36.

First a trial arm by cycle model was fitted and the interaction term was tested for significance (Wald test chi-square on 6 df, p=0.25). There being no formal evidence for different treatment effects with cycle, the simpler trial arm + cycle model was fitted. This analysis showed that the estimated odds ratio of a lower (i.e. better) score for Acupressure compared to control is e0.4255 = 1.53 , (1.12, 2.09) and the estimated odds ratio of a lower (i.e. better) score for Sham Acupressure compared to control is e0.3823 = 1.47 , (1.06, 2.02).

 Longitudinal analyses of secondary outcomes

MASCC Antiemesis Tool: acute and delayed nausea
These were both scored 0-10 and were highly skewed with large proportions on the 0 extreme. For regression analysis new ordered factors with 5 levels were created. The regression analyses followed a similar approach to that employed for the Rhodes nausea experience described earlier. For both outcomes there was no evidence of an arm x cycle interaction but both outcomes exhibited evidence of an arm x gender interaction. Table 4 show the arm effect estimates.

INSERT TABLE 4 HERE

MASCC Antiemesis Tool- acute and delayed Vomiting
The mean (days 0-6) Rhodes vomiting experience data was highly skewed. These were grouped 0, (0,1], (1,2], (2,3] and >3. When analysed with a longitudinal proportional odds model there was no evidence of any trial arm effects (p=0.47, Wald test). The MASCC Antiemesis Tool- acute vomiting data was recorded as the number of times in the 24 hours since chemotherapy. Descriptively there was no difference between the trial arms. The MASCC Antiemesis Tool-delayed vomiting was recorded as the number of days on which vomiting occurred 0-4. When analysed with a longitudinal proportional odds model there was no evidence of any trial arm effects (p=0.69, Wald test).

Results related to Hospital Anxiety & Depression Scale and FACT-G scale
These were assessed at baseline and at cycles 1-4. Longitudinal linear models were fitted (Generalised Estimating Equation using unstructured covariance matrices) to the cycle 1-4 data using the relevant baseline variable as a covariate along with factors representing cycle and arm. There was no evidence of any trial arm effects on mean values as can be seen in Table 5.  

INSERT TABLE 5 HERE

Discussion
Despite the higher proportion of patients showing no nausea in the acupressure group, the results of the trial show that there were no statistically significant differences between the three trial arms in relation to nausea experience. Patients in both wristbands arms had a higher odds ratio in improving their nausea experience compared to standard care arm, with the sham arm having a higher odds ratio than the acupressure arm. There was a significant gender effect, with females in both wristband groups showing significant improvements compared to males.

Other trials in the past have also shown no significant changes from the use of acupressure in relation to nausea and vomiting management during chemotherapy administration. A review by Lee et al37 examined the results of seven trials of acupressure, where four had positive results and three negative, highlighting that the overall effect of acupressure is strongly suggestive but not conclusive. No significant differences were reported in another trial of 160 women with regards to acute nausea and vomiting, although significant differences were reported with regards to delayed nausea and vomiting38. In the largest trial of its kind (n=739), Roscoe et al22 showed that patients experienced less nausea in the first day of chemotherapy in the acupressure arms, but there were no significant differences in relation to delayed symptoms. Also the authors identified a strong gender effect, with men in an acustimulation arm improving but not women, the opposite way of the results of the current trial. Roscoe et al15 also showed in a small sample of 27 patients (25 women and 2 men) no statistically significant differences in average severity of nausea were observed between acustimulation of the P6 point, sham acustimulation and standard carearms. However, the data showed a difference close to statistical significance in the severity of delayed nausea reported during active acustimulation compared to no acustimulation (P =0.06). In addition, patients took fewer antinausea pills during the active-acustimulation cycle of this experiment compared to the no-acustimulation phase (P <0 .05). Negative results have been shown in relation to acupressure and nausea/vomiting symptoms in a large trial of 340 women during labour and delivery39. In a trial of acupuncture versus sham acupuncture during radiotherapy, authors also showed less nausea and vomiting in both the real and sham acupuncture arms compared to standard care, and justified this due to non-specific effects of a general care or high patient expectancy40 which may partly explain our results too.

Key issues in most of the past studies showing positive results include the lack of standardised antiemetic use in the trial participants and inclusion of only or mostly female subjects. If our trial included only the female sub-sample, the results would have also been positive in our case. Also, it seems that the vast majority of positive studies in the literature include small sample sizes (<100 participants), whereas the negative studies (or partly negative) have much larger sample sizes; this suggests that effects observed in methodologically weaker studies cannot always be sustained when larger and more robust trials are done. Furthermore, other studies in the past have shown that expectancy22,41, age and anxiety25,42 together with the antiemetic potential of the chemotherapy are important predictors of and can affect the outcome of acupressure, but in our trial, while unidimensionally these were also important, in a multivariate model only gender showed significant effect.

Our findings suggest a placebo or non-specific effect of the intervention arms. Placebo effects are viewed as a form of interpersonal healing, distinct from spontaneous natural healing or technological healing that depends on physiologically active pharmacological products or procedures43. Alkaissi et al44 have suggested that acupressure does indeed have a placebo effect in relation to nausea after 24hrs, although correct stimulation of the P6 point is needed to observe decreased rescue antiemetic use and decreased vomiting. Research also suggests that there are different placebo responses, each of which may be influenced by different psychological and neurobiological mechanisms depending on the context the placebo is given45. The literature also shows that placebos have actual biological effects on the brain and body and are more than response biases. They conclude in their review that placebo effects reflect mind-brain-body relationships and as such we should not ‘resort to eliminative materialism or forms of dualism that completely divide the mind from the body’ (p. 586) 45.

Trials of acupressure pose a specific problem with regards to the blinding and the choice
of placebo, particularly when outcome measures are subjective. We have chosen to use the same wristbands in both the real and sham group so they can look identical, with the real acupressure groups instructed to have the button pressing the P6 point whereas the sham group were instructed to have the button away from the P6 point in the other side of the arm. We have observed during interviews carried out concurrently with the trial that some patients (2/9 in the sham group) used the wristbands as in the real group because they had looked on the internet or saw others wearing them properly. This may have contaminated our results. It was not possible to create a different wristband that would look identical with the real ones but would have no button nor exert pressure, as they were elastic bands. As reported by Sinha et al39 (through observations from their colleagues in the department of Industrial and Manufacturing Engineering, Penn State University) elastic bands result in some pressure. This suggests that the pressure of the band in the area proximal to the P6 point, irrespective of the presence of a button pressing the P6 point, may have produced some positive results. 

Our sample had generally low levels of nausea and/or vomiting. This may be due to the fact that we have standardized antiemetic use in our study and an inclusion criterion was receiving antiemetics as per MASCC antiemetic guidelines. This low level of experienced symptoms may be a reason for not showing significant differences in the current trial, as we have shown in another observational study of nearly 1,000 patients that use of antiemetics during chemotherapy according to MASCC guidelines is associated with significantly improved nausea/vomiting symptoms46. 

A limitation of the trial may be the missing data for the primary outcome. However, the proportion of cases missing the primary outcome (28%) is of similar order to that anticipated at the design stage (33%). Originally 90% power had been planned for a standardized difference in means of around 0.48. For pragmatic reasons the study power was reduced to 80% so that it could complete in a reasonable timeframe. The attained power that the final sample size with complete data for the primary outcome (n=361) delivered was 80% for a standardized difference in means of 0.46.  Also, another limitation which needs to be carefully considered in future trials is the choice of sham wristbands, which in our case may not have been the most optimal design.

Conclusions and research recommendations
Despite several acupressure antiemetic trials suggesting a beneficial effect, the trial heterogeneity and inconsistent findings prevented any definitive conclusions being drawn. Our study, using a strong methodological design and standardization of antiemetics, showed no significant differences in the use of acupressure wristbands for the management of nausea and vomiting during chemotherapy. However, clinically, the improved levels of nausea in both wristband arms need some attention as patients in both arms tended to show some improvement. However, as minimally important differences in relation to chemotherapy-related nausea and vomiting are currently not established, some caution is necessary with this comment. Also, the use of wristbands led to lower health care utilization (although this did not reach statistical significance). Bands are well-accepted, are low cost and safe additions to antiemetic drugs, but the ethical aspects of suggesting the use of potentially non-effective interventions that lead to lower health care costs and health care utilization needs some careful consideration. There is a sufficiently encouraging signal and and a suggestion of potential health resource use benefits to justify exploration of acupressure in  further trials using both no intervention and sham acupressure controls. Questions that need to be answered in the future include whether other forms of acupressure, such as regular finger acupressure or Korean hand acupressure, could be more effective than wristband acupressure. A meta-analysis of existing data on acupressure wristbands may be an appropriate way to provide a more concrete answer as to whether acupressure wristbands are effective in managing nausea and/or vomiting during chemotherapy.
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2 weekly CT	No	122/451 (27%)	0.75
	Yes	14/46 (30%)	
Baseline anxiety	Normal (0-7)	50/250 (20%)	0.16





* Chi-square tests of equal proportions.
** Three were all allocated to “No acupressure” but there are no records in the trial database for these 3 cases i.e. no completed screening forms and no returned data forms. These 3 cases are the discrepant ones between n=500 and n=497.


Table 3. Mean Rhodes nausea experience (days 0-6). Entries are median (min, lower quartile, upper quartile, max):

Cycle	None	Sham	Acu
1	1.43 (0, 0, 3.71, 8.57)N=117	0.57 (0, 0, 2.64, 9.17)N=118	(0, 0, 2.97, 7.50)N=126
2	1.71 (0, 0, 3.43, 10.14)N=109	0.71 (0, 0, 2.14, 10.29)N=105	0.93 (0, 0, 3.43, 9.57)N=114
3	1.14 (0, 0, 3.86, 11.86)N=96	0.71 (0, 0, 2.29, 9.71)N=88	0.43 (0, 0, 3.00, 10.14)N=103
4	1.14 (0, 0, 4.00, 9.14)N=81	0.43 (0, 0, 2.43, 8.57)N=77	0.00 (0, 0, 1.82, 9.86)N=90


Table 4. Longitudinal outcomes (i.e. cycle averaged effects for MASCC Antiemesis Tool acute nausea)
Cycle averaged effects for MAT- acute nausea
Effect	Odds ratio estimate*	95% CI
Sham to None (Males)	0.32	(0.12, 0.82)
Sham to None (Females)	1.62	(1.04, 2.53)
Acu to None (Males)	0.63	(0.21, 1.96)
Acu to None (Females)	1.27	(0.82, 1.96)
 Cycle averaged effects for MAT- delayed nausea
Effect	Odds ratio estimate*	95% CI
Sham to None (Males)	0.54	(0.21, 1.40)
Sham to None (Females)	1.74	(1.12, 2.68)
Acu to None (Males)	0.99	(0.37, 2.69)
Acu to None (Females)	1.49	(0.97, 2.28)
 
* From a proportional odds model (Generalised Estimating Equation fit) adjusting for gender, age group, emetogenic risk group and cycle.

Table 5. Analysis of Hospital Anxiety & Depression Scale and FACT-G data by trial arm









PWB: Physical well-being; SFWB: social well-being; EWB: emotional well-being; FWB: functional well-being. The last two columns show the estimated difference in means from the ‘None’ group from model (2) with standard errors in brackets. These effects are very small and non-significant.
1) Wald test from a y.baseline + cycle*arm model.





Figure 1: Patient recruitment CONSORT diagram

											500 patients consentedto ANCHoR											
																						
		168 randomised to acupressure group(11 withdrawn / died*)						166 randomised to no wrist bands group (15 withdrawn / died**)						166 randomised to sham acupressure group(10 withdrawn / died***)		
																						
36 lost to follow up(no outcome data)(6 withdrawn / died)		132 patients retained in trial		45 lost to follow up(no outcome data)(7 withdrawn / died)		121 patients retained in trial		47 lost to follow up(no outcome data)(7 withdrawn)		119 patients retained in trial
																						
				50 patients, partial data1(5 with-drawn)		82 patients, complete data						41 patients, partial data1(8 with-drawn / died)		80 patients, completedata						43 patients, partial data1(3 with-drawn)		76 patients, complete data

*	eyesight problems: 1	**	chemotherapy changed: 1	***	difficulties with chemotherapy: 1
	felt very ill: 1		chemotherapy stopped: 2		chemotherapy stopped: 1
	lymphoedema: 1		didn’t receive wristbands: 4		ineligible re. screening criteria: 4
	sore arms after chemotherapy: 1		felt very ill: 2		sore arms after chemotherapy: 2
	uncomfortable wristbands: 2		no reason given: 3		uncomfortable wristbands: 1
	unhappy with questionnaires: 1		died:	3		no reason given: 1
	no reason given: 2				
	died: 2		










Figure 2. Box and whisker plot of the primary outcome by trial arm
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